Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adeno-associated virus encoding anti-CD19/anti-CD3 bispecific diabody VNX-101

An off-the-shelf preparation of adeno-associated virus (AAV) encoding the anti-CD19/anti-CD3 bispecific diabody GP101, with potential immunostimulating and antineoplastic activities. Upon administration, AAV encoding anti-CD19/anti-CD3 bispecific diabody VNX-101 induces the secretion of GP101 by hepatocytes and other cells into the bloodstream. GP101 binds to both the CD3 antigen on T cells and the CD19 antigen expressed on tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AAV encoding anti-CD19/anti-CD3 bispecific diabody GP101 VNX-101
AAV encoding anti-CD19/anti-CD3 bispecific diabody VNX-101
AAV encoding anti-CD19/anti-CD3 bispecific T-cell engager VNX-101
AAV.CD3/CD19
Code name:VNX 101
VNX-101
VNX101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search